GB0706070D0 - Nucleic acids - Google Patents

Nucleic acids

Info

Publication number
GB0706070D0
GB0706070D0 GBGB0706070.0A GB0706070A GB0706070D0 GB 0706070 D0 GB0706070 D0 GB 0706070D0 GB 0706070 A GB0706070 A GB 0706070A GB 0706070 D0 GB0706070 D0 GB 0706070D0
Authority
GB
United Kingdom
Prior art keywords
nucleic acid
cell epitopes
antibody
heterologous
nucleic acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0706070.0A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scancell Ltd
Original Assignee
Scancell Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scancell Ltd filed Critical Scancell Ltd
Priority to GBGB0706070.0A priority Critical patent/GB0706070D0/en
Publication of GB0706070D0 publication Critical patent/GB0706070D0/en
Priority to CA2681531A priority patent/CA2681531C/en
Priority to BRPI0808599A priority patent/BRPI0808599A2/pt
Priority to KR1020097021806A priority patent/KR20100015699A/ko
Priority to PL08735583T priority patent/PL2134357T3/pl
Priority to ES10152624T priority patent/ES2375463T3/es
Priority to KR1020157000952A priority patent/KR20150013357A/ko
Priority to EP10152624A priority patent/EP2193803B1/en
Priority to DK08735583.0T priority patent/DK2134357T3/en
Priority to KR1020177009184A priority patent/KR20170040387A/ko
Priority to CN201310487984.6A priority patent/CN103667304B/zh
Priority to JP2010500296A priority patent/JP5415399B2/ja
Priority to AT10152624T priority patent/ATE529128T1/de
Priority to PT87355830T priority patent/PT2134357T/pt
Priority to DK10152624.2T priority patent/DK2193803T3/da
Priority to KR1020167020295A priority patent/KR101729458B1/ko
Priority to PCT/EP2008/053761 priority patent/WO2008116937A2/en
Priority to ES08735583.0T priority patent/ES2638188T3/es
Priority to PT10152624T priority patent/PT2193803E/pt
Priority to AU2008231723A priority patent/AU2008231723B2/en
Priority to CN200880017669.4A priority patent/CN101678092B/zh
Priority to EP08735583.0A priority patent/EP2134357B1/en
Priority to US12/566,465 priority patent/US8742088B2/en
Priority to ZA2009/07242A priority patent/ZA200907242B/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
GBGB0706070.0A 2007-03-28 2007-03-28 Nucleic acids Ceased GB0706070D0 (en)

Priority Applications (24)

Application Number Priority Date Filing Date Title
GBGB0706070.0A GB0706070D0 (en) 2007-03-28 2007-03-28 Nucleic acids
EP08735583.0A EP2134357B1 (en) 2007-03-28 2008-03-28 Nucleic acids
CN201310487984.6A CN103667304B (zh) 2007-03-28 2008-03-28 核酸
AT10152624T ATE529128T1 (de) 2007-03-28 2008-03-28 Nukelinsäure kodierend für gp100 und trp2 epitope tragende immunoglobine
KR1020097021806A KR20100015699A (ko) 2007-03-28 2008-03-28 핵산
PL08735583T PL2134357T3 (pl) 2007-03-28 2008-03-28 Kwasy nukleinowe
ES10152624T ES2375463T3 (es) 2007-03-28 2008-03-28 �?cidos nucleicos que codifican inmunoglobulinas que portan ep�?topos de trp2 y gp100.
KR1020157000952A KR20150013357A (ko) 2007-03-28 2008-03-28 핵산
EP10152624A EP2193803B1 (en) 2007-03-28 2008-03-28 Nucleic acids encoding immunoglobins carrying gp100 and TRP2 epitopes
DK08735583.0T DK2134357T3 (en) 2007-03-28 2008-03-28 nucleic acids
KR1020177009184A KR20170040387A (ko) 2007-03-28 2008-03-28 핵산
CA2681531A CA2681531C (en) 2007-03-28 2008-03-28 Immunoglobulin heavy chains comprising heterologous t-cell epitopes
JP2010500296A JP5415399B2 (ja) 2007-03-28 2008-03-28 核酸
BRPI0808599A BRPI0808599A2 (pt) 2007-03-28 2008-03-28 "ácido nucléico, vacina, composição farmacêutica, uso de um ácido nucléico e método para estimular uma imunoresposta versus um epítopo das células t"
PT87355830T PT2134357T (pt) 2007-03-28 2008-03-28 Ácidos nucleicos
DK10152624.2T DK2193803T3 (da) 2007-03-28 2008-03-28 Nukleinsyrer, der koder for immunoglobiner, som bærer gp100 og TRP2-epitoper
KR1020167020295A KR101729458B1 (ko) 2007-03-28 2008-03-28 핵산
PCT/EP2008/053761 WO2008116937A2 (en) 2007-03-28 2008-03-28 Nucleic acids
ES08735583.0T ES2638188T3 (es) 2007-03-28 2008-03-28 Ácidos nucleicos
PT10152624T PT2193803E (pt) 2007-03-28 2008-03-28 Ácidos nucleicos que codificam imunoglobulinas que possuem epítopos de gp100 e trp2
AU2008231723A AU2008231723B2 (en) 2007-03-28 2008-03-28 Nucleic acids
CN200880017669.4A CN101678092B (zh) 2007-03-28 2008-03-28 核酸
US12/566,465 US8742088B2 (en) 2007-03-28 2009-09-24 Nucleic acids encoding antibodies or portions thereof comprising a heterologous T cell epitope and their use in modulating T cell responses
ZA2009/07242A ZA200907242B (en) 2007-03-28 2009-10-16 Nucleic acids

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0706070.0A GB0706070D0 (en) 2007-03-28 2007-03-28 Nucleic acids

Publications (1)

Publication Number Publication Date
GB0706070D0 true GB0706070D0 (en) 2007-05-09

Family

ID=38050410

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0706070.0A Ceased GB0706070D0 (en) 2007-03-28 2007-03-28 Nucleic acids

Country Status (16)

Country Link
US (1) US8742088B2 (https=)
EP (2) EP2193803B1 (https=)
JP (1) JP5415399B2 (https=)
KR (4) KR20100015699A (https=)
CN (2) CN103667304B (https=)
AT (1) ATE529128T1 (https=)
AU (1) AU2008231723B2 (https=)
BR (1) BRPI0808599A2 (https=)
CA (1) CA2681531C (https=)
DK (2) DK2134357T3 (https=)
ES (2) ES2375463T3 (https=)
GB (1) GB0706070D0 (https=)
PL (1) PL2134357T3 (https=)
PT (2) PT2193803E (https=)
WO (1) WO2008116937A2 (https=)
ZA (1) ZA200907242B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0706070D0 (en) 2007-03-28 2007-05-09 Scancell Ltd Nucleic acids
GB201214007D0 (en) 2012-08-07 2012-09-19 Scancell Ltd Anti-tumour immune responses to modified self-epitopes
US10441649B2 (en) 2015-02-02 2019-10-15 The University Of Birmingham Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes
WO2017210149A1 (en) * 2016-05-31 2017-12-07 Igc Bio, Inc. Compositions and methods for generating an antibody library
US11419928B2 (en) 2017-10-25 2022-08-23 The Johns Hopkins University Methods and compositions for treating cancer
GB201815041D0 (en) 2018-09-14 2018-10-31 Scancell Ltd Epitopes
GB201910900D0 (en) 2019-07-31 2019-09-11 Scancell Ltd Modified fc-regions to enhance functional affinity of antibodies and antigen binding fragments thereof
WO2021195089A1 (en) 2020-03-23 2021-09-30 Sorrento Therapeutics, Inc. Fc-coronavirus antigen fusion proteins, and nucleic acids, vectors, compositions and methods of use thereof
CN111423504B (zh) * 2020-04-17 2021-03-26 安徽高安生物医学科技有限公司 黑色素瘤特异性抗原肽、肽复合物以及人工抗原呈递细胞
US20230310584A1 (en) * 2020-08-26 2023-10-05 Scancell Limited Nucleic acids encoding a polypeptide comprising a modified fc region of a human igg1 and at least one heterologous antigen
GB202314361D0 (en) * 2023-09-19 2023-11-01 Scancell Ltd Vaccine compositions and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5969109A (en) * 1990-02-28 1999-10-19 Bona; Constantin Chimeric antibodies comprising antigen binding sites and B and T cell epitopes
DE69522216T2 (de) 1994-05-13 2002-05-02 Biovation Ltd Zielzellen-bindende chimäre Peptide
CA2195642A1 (en) * 1994-07-27 1996-02-08 Andreas Suhrbier Polyepitope vaccines
US5698679A (en) * 1994-09-19 1997-12-16 National Jewish Center For Immunology And Respiratory Medicine Product and process for targeting an immune response
AUPO784197A0 (en) * 1997-07-10 1997-08-07 Csl Limited Treatment of nasopharyngeal carcinoma
BR9815289A (pt) * 1997-11-14 2001-12-26 Euro Celtique Sa Imunoglobulina modificada, molécula, ácidonucleico isolado, célula contendo o mesmo, animalnão-humano recombinante, composiçãofarmacêutica, composição de vacina, processospara identificar ou medir ou detectar um antìgenode câncer, um antìgeno de um agente de doençainfecciosa, um ligante, e um receptor em umaamostra a ser testada, kits para detecção de umantìgeno de câncer, de um antìgeno de um agentede doença infecciosa, de um receptor celular paraum agente de doença infecciosa, de um ligante, e deum antìgeno de câncer, processos de diagnósticoou de exame para a presença de ou umapredisposição para desenvolvimento de um câncertipificado pela presença aumentada de umantìgeno de câncer, e para a presença de umagente de doença infecciosa, processos detratamento ou de prevenção de um câncertipificado pela presença de um antìgeno de câncer,de uma doença infecciosa tipificada pela presençade um antìgeno de agente de doença infecciosa, ede uma doença causada por um agente de doençainfecciosa que se liga em um receptor celular,processos para modulação de atividade de umprimeiro membro de um par de ligação, processo deprodução de uma imunoglobulina modificada,processo de produção de um ácido nucleicocodificador de imunoglobulina modificada, e, ácidonucleico isolado
CA2369616C (en) 1999-04-27 2009-09-15 Eurogen Holding, S.A. Somatic transgene immunization and related methods
US7067110B1 (en) * 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
GB0102145D0 (en) * 2001-01-26 2001-03-14 Scancell Ltd Substances
GB0111628D0 (en) 2001-05-11 2001-07-04 Scancell Ltd Binding member
AU2002331704A1 (en) * 2001-08-22 2003-03-10 The Government Of The United States Of America, Represented By The Secretary, Department Of Health A Peptides of melanoma antigen and their use in diagnostic, prophylactic and therapeutic methods
WO2004030616A2 (en) * 2002-09-17 2004-04-15 Antigen Express, Inc. Ii-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES
GB0706070D0 (en) 2007-03-28 2007-05-09 Scancell Ltd Nucleic acids

Also Published As

Publication number Publication date
ATE529128T1 (de) 2011-11-15
DK2193803T3 (da) 2012-02-13
CA2681531C (en) 2017-11-28
EP2134357A2 (en) 2009-12-23
EP2193803B1 (en) 2011-10-19
DK2134357T3 (en) 2017-09-11
CN103667304B (zh) 2018-02-02
AU2008231723B2 (en) 2013-05-16
US20100260806A1 (en) 2010-10-14
CN103667304A (zh) 2014-03-26
CN101678092B (zh) 2014-04-02
KR20160091458A (ko) 2016-08-02
KR101729458B1 (ko) 2017-04-21
ZA200907242B (en) 2010-11-24
BRPI0808599A2 (pt) 2019-01-08
CN101678092A (zh) 2010-03-24
PT2134357T (pt) 2017-08-29
JP5415399B2 (ja) 2014-02-12
PT2193803E (pt) 2012-01-16
WO2008116937A2 (en) 2008-10-02
ES2375463T3 (es) 2012-03-01
PL2134357T3 (pl) 2018-03-30
JP2010522550A (ja) 2010-07-08
AU2008231723A1 (en) 2008-10-02
KR20150013357A (ko) 2015-02-04
EP2134357B1 (en) 2017-05-31
US8742088B2 (en) 2014-06-03
WO2008116937A3 (en) 2009-01-22
ES2638188T3 (es) 2017-10-19
KR20170040387A (ko) 2017-04-12
KR20100015699A (ko) 2010-02-12
EP2193803A1 (en) 2010-06-09
CA2681531A1 (en) 2008-10-02

Similar Documents

Publication Publication Date Title
ZA200907242B (en) Nucleic acids
PE20140133A1 (es) Nuevas proteinas de union a antigenos
RU2016119152A (ru) Стабильные и растворимые антитела, ингибирующие vegf
NZ623347A (en) Novel anti-dr5 antibody
AR078778A1 (es) Proteinas de union a antigenos de il-23
ES2430068T3 (es) Proteínas de unión a antígeno del factor de crecimiento de tipo factor de crecimiento epidérmico de unión a heparina
IL261585A (en) Antigen-binding human proteins that bind beta-klotho, fgf receptors and their complexes
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
CL2013003140A1 (es) Un anticuerpo monoclonal humano aislado o fragmento de union a antigeno del mismo que se une a masp-2 humana; molecula de acido nucleico, casette de expresion, celula que la expresa, metodo de produccion, composicion que la contiene, articulo que lo contiene.
AU2016204274A1 (en) Antibodies that bind to OX40 and their uses
NZ597692A (en) Anti-IGF antibodies
PE20161439A1 (es) Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos
PE20091963A1 (es) Anticuerpos anti-flt3
PE20161221A1 (es) Anticuerpos de il-21
PE20141660A1 (es) PROTEINAS DE UNION A ANTIGENO DE TNF-ALFA CON UNION A FcRn INCREMENTADA
PE20120622A1 (es) Anticuerpos anti-vegf y sus usos
AR105026A1 (es) ANTICUERPOS MADURADOS POR AFINIDAD Y HUMANIZADOS PARA FcRH5 Y MÉTODOS PARA SU USO
WO2012045481A3 (en) Antibody targeting osteoclast-related protein siglec-15
PE20161033A1 (es) Proteinas de union al antigeno gitr
NZ603972A (en) Anti-fgfr2 antibodies
NZ603529A (en) Antibodies to human gdf8
CO6231038A2 (es) Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos
JP2010522550A5 (https=)
CL2010000470A1 (es) Anticuerpo que se une a efrina-b2 que comprende la region variable de la cadena liviana y pesada bvr-l1, hvr-l2, hvr-h1, hvr-h2 y hvr-h3; polinucleotido que codifica dicho anticuerpo; vector y celula huesped que comprende al polinucleotido; metodo para elaborar el anticuerpo, detectar efrina-b2; y uso de dicho anticuerpo.
SA520420339B1 (ar) أجسام مضادة مُطعمة ببتيد أذيني مدر للصوديوم

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)